Pharmacovigilance (PV) operates in an environment where regulatory decisions, patient safety evaluations, and benefit–risk assessments depend directly on the quality, integrity, and traceability of safety data. While computerized system validation remains a fundamental regulatory expectation, validation alone does not guarantee that pharmacovigilance data are accurate, complete, consistent, and fit for their intended purpose throughout their lifecycle.

Regulators increasingly expect marketing authorization holders to demonstrate effective data governance across all pharmacovigilance activities. This includes clear ownership of safety data, defined accountability for data entry and review, controlled management of data changes, and oversight of data flow between systems, vendors, affiliates, and local partners.

Data governance in pharmacovigilance therefore extends beyond technical compliance. It establishes the framework through which organizations maintain confidence that safety information used for case processing, signal detection, aggregate reporting, risk management, and regulatory decision-making remains reliable from initial receipt through archival.

Why Data Governance Matters in Pharmacovigilance

Pharmacovigilance data originate from multiple sources, including spontaneous reports, literature monitoring, clinical studies, medical information inquiries, partners, distributors, and digital channels. These data often move across several operational interfaces before becoming part of the official safety database.

At each point in the data lifecycle, risks may arise, such as:

• incomplete case information,
• duplicate records,
• delayed data transfer,
• inconsistent coding,
• undocumented corrections,
• reconciliation gaps between source systems.

Weak governance in these areas may affect regulatory compliance and may also compromise timely identification of safety signals.

Regulatory authorities expect organizations to maintain demonstrable control over data throughout its lifecycle. This includes ensuring that data are attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, and available — principles commonly aligned with the scientific concept of ALCOA+.

Regulatory Expectations for Pharmacovigilance Data Governance

Pharmacovigilance data governance is supported by several regulatory frameworks and good practice expectations.

The European Medicines Agency’s Good Pharmacovigilance Practices emphasize that marketing authorization holders must maintain documented pharmacovigilance systems with defined responsibilities, oversight arrangements, and adequate quality systems.

The International Council for Harmonisation guidance, including ICH E2D and ICH E2E, further reinforces expectations regarding data handling, case management, and data quality.

In practical terms, regulators expect organizations to demonstrate:

• defined ownership of safety data,
• controlled procedures governing data creation, modification, transfer, and reconciliation,
• traceability of changes through audit trails,
• oversight of outsourced pharmacovigilance activities,
• documented governance of interfaces between systems and external parties,
• periodic monitoring of data quality through quality management activities.

Importantly, inspectors increasingly evaluate whether organizations can explain not only how systems are validated, but also how data remain trustworthy after implementation during routine operations.

Data Lifecycle Governance in Pharmacovigilance

Effective governance should apply across the entire pharmacovigilance data lifecycle.

Data Capture

Safety information must be captured from source documents in a timely and complete manner. Organizations should establish procedures that define:

• minimum information required for case validity,
• source document retention requirements,
• handling of follow-up information,
• responsibilities for data entry and medical review.

Data capture controls should ensure that source information remains traceable to entered case data.

Data Processing and Coding

During case processing, structured governance is needed for:

• standardized medical terminology coding using MedDRA,
• seriousness assessment,
• expectedness determination,
• causality assessment,
• management of case amendments.

Clear procedural controls help maintain consistency across case processors, affiliates, and vendors.

Data Transfer and Interfaces

Safety data often move between:

• safety databases,
• literature screening platforms,
• medical information systems,
• clinical databases,
• partner organizations.

Each interface should be governed by documented transfer specifications, reconciliation procedures, exception handling mechanisms, and defined escalation pathways.

Data Retention and Archiving

Data governance also extends to archival controls. Organizations should ensure that pharmacovigilance records remain retrievable, protected against unauthorized alteration, and retained according to applicable regulatory retention requirements.

Roles and Responsibilities in Pharmacovigilance Data Governance

Clear accountability is central to effective governance.

Qualified Person for Pharmacovigilance / Global PV Leadership

The Qualified Person for Pharmacovigilance or designated global pharmacovigilance leadership should maintain oversight of governance arrangements affecting the pharmacovigilance system. While operational ownership may be distributed, strategic oversight of data integrity risks remains essential.

Key responsibilities typically include:

• ensuring governance frameworks are established,
• reviewing significant data quality risks,
• ensuring escalation of critical compliance issues,
• maintaining visibility of systemic data-related deviations.

Pharmacovigilance Operations

PV operations teams are generally responsible for:

• accurate case entry,
• case quality review,
• reconciliation execution,
• compliance with procedural requirements,
• escalation of data inconsistencies.

Operational personnel are often the first line of control.

Quality Assurance

Quality functions provide independent oversight through:

• audits,
• compliance monitoring,
• procedural review,
• CAPA follow-up,
• periodic quality trend analysis.

Information Technology and System Owners

IT and system owners support governance through:

• access management,
• audit trail maintenance,
• controlled change management,
• backup and business continuity arrangements,
• interface support.

Their role extends beyond validation into operational control of data environments.

Vendors, Partners, and Affiliates

Where pharmacovigilance activities are outsourced, contractual governance must define:

• data ownership,
• transfer timelines,
• reconciliation responsibilities,
• quality expectations,
• escalation procedures.

Regulators expect marketing authorization holders to retain oversight even where operational activities are delegated.

Core Regulatory Procedures Supporting Data Governance

A robust pharmacovigilance governance framework is usually supported by controlled procedures.

Data Entry and Data Quality Review

Organizations should define procedures for:

• source-to-database verification,
• mandatory field completion,
• duplicate management,
• quality review criteria,
• correction of discrepancies.

Reconciliation

Reconciliation procedures should cover alignment between:

• safety databases,
• medical information systems,
• product quality complaint systems,
• literature databases,
• partner data sources.

Effective reconciliation should define frequency, ownership, documentation requirements, and escalation of unresolved mismatches.

Change Control

Changes affecting pharmacovigilance data structures, workflows, interfaces, or operational processes should be subject to formal change control. Risk assessment should evaluate potential impact on safety reporting, data integrity, and regulatory compliance.

Access Control

Role-based access management should ensure that users have appropriate permissions aligned with operational responsibilities. Periodic access reviews are an important governance control.

Deviation and CAPA Management

Data governance requires formal management of:

• data quality deviations,
• root cause investigations,
• corrective actions,
• preventive actions,
• effectiveness verification.

Governance Beyond Validation

System validation confirms that a computerized system performs as intended under defined conditions. However, pharmacovigilance data governance addresses a broader question: whether the data generated, modified, transferred, and maintained within that validated environment remain reliable over time.

A validated system may still produce poor-quality data if:

• users are inadequately trained,
• procedures are weak,
• reconciliations are not performed,
• ownership is unclear,
• interfaces are poorly controlled,
• deviations are not investigated.

For this reason, regulators increasingly view data governance as an operational quality discipline rather than solely a technical validation exercise.

Building a Mature Pharmacovigilance Data Governance Framework

Organizations seeking mature governance should focus on integrating governance into routine pharmacovigilance operations rather than treating it as a standalone compliance activity.

A practical framework typically includes:

• documented data ownership,
• lifecycle-based procedural controls,
• risk-based monitoring of data quality metrics,
• periodic governance review forums,
• vendor oversight mechanisms,
• continuous improvement through deviation trending and CAPA effectiveness.

When embedded effectively, data governance strengthens inspection readiness while improving confidence in benefit–risk decision-making.

Establishing effective pharmacovigilance data governance frameworks often requires integrated operational oversight across quality management, reconciliation processes, compliance monitoring, and vendor governance, areas supported through Baupharma’s pharmacovigilance services: Baupharma Pharmacovigilance Services⁠

Key Takeaways

• Pharmacovigilance data governance extends beyond computerized system validation.
• Regulators expect lifecycle control of safety data from receipt through archival.
• Clear ownership, accountability, and documented procedures are essential.
• Reconciliation, change control, access management, and deviation handling are core governance mechanisms.
• Outsourcing does not transfer ultimate accountability for pharmacovigilance data quality.
• Effective data governance supports both regulatory compliance and patient safety decision-making.